Candidate: COVID-19 vaccine

Category: VAX

Type: Whole inactivated virus-based vaccine

Status: Panacea Biotec said June 10 it has partnered with Refana to launch an Ireland-based joint venture company to develop a COVID-19 vaccine. Panacea Biotec will oversee product development and commercial manufacturing, with the joint venture being responsible for clinical development and regulatory submissions worldwide. Panacea and Refana said they will undertake sales and distribution of the vaccine in their respective territories.

“Our collaboration with Refana aims to manufacture over 500 million doses of our COVID-19 candidate vaccine, with over 40 million doses expected to be available for delivery early next year,” Panacea Biotec managing director Rajesh Jain, PhD, said in a statement. The 500 million doses would be manufactured over 12 months, stated Phillip Schwartz, PhD, Chief Scientific and Medical advisor to U.S.-registered Refana.

New Dehli-based Panacea Biotec received an investment of up to INR 992 Crores ($144 million) in 2019 that was led by India Resurgence Fund (IndiaRF), a joint venture of Piramal Enterprises and Bain Capital Credit.

COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:



Previous articleCapricor Therapeutics – Exosome-based vaccine program
Next articleQualigen Therapeutics – AS1411